It is upregulated in many cancers, stabilizing otherwise unstable oncogenic drivers such as mutant EGFR46, mutant BRAF47, 48, wild-type and mutant HER2, as well as certain anti-apoptotic factors49. This evidence concerns the gene ERBB2 and cancer.